Art. -Nr.: HY-174806

Y040-7904

(Synonyms: 7-(β-D-Galactopyranosyloxy)-4-phenylchromen-2-one)

Kundenbewertung

Based on 1 Customer Validation

Y040-7904 is a mitophagy activator. Y040-7904 enhances mitophagy by promoting mitochondria transport to autophagosomes and the fusion of autophagosomes with autolysosomes. Y040-7904 induces mitophagy through the SIRT1/FoxO3 pathway. Y040-7904 upregulates the levels of Parkin, PINK1, and LC3II/I. Y040-7904 reduces amyloid-β (Aβ) accumulation in both in vitro and in vivo models of Alzheimer’s disease.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.36%
CAS. Nr.: 889662-19-5
Formel: C₂₀H₁₈O₇
Molecular Weight:370.35

Speicherung:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Y040-7904 Chemical Structure

CAS. Nr.: 889662-19-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

In Vitro

Y040-7904 (20 μM, 24 h) induces a detectable increase in mitolysosomes and increases the proportions of mitophagosomes (9%) and mitolysosomes (18%), higher than those induced by the two established mitophagy inducers, Urolithin A (HY-100599) and UMI-77 (HY-18628), in HT22 cells^[1].

Y040-7904 (5-20 μM, 24 h) facilitates the expression of mitophagy-related proteins PINK1 and Parkin through the SIRT1-FoxO3a pathway, ultimately resulting in an elevation in mitophagy levels in HT22 cells and N2a/APPswe cells^[1].

Y040-7904 (5-20 μM, 24 h) enhances mitochondrial biogenesis by upregulateing the expression of MFN2, TIM23, and TOM20 in HT22 cells^[1].

Y040-7904 (5-20 μM, 24 h) mitigates APP and Aβ1-42 accumulation in N2a/APPswe cells^[1].

Y040-7904 (5-20 μM, 24 h) upregulates the levels of Parkin, PINK1, and LC3II/I in N2a/APPswe cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

HT22 cells, PINK1 silenced HT22 cells
Concentration:

5, 10, and 20 μM
Incubation Time:

24 h
Result:

Increased the levels of mitophagy-related proteins, including PINK1, Parkin, phosphorylated Ser65-ubiquitin (pUb), and LC3B-II/LC3B–I in a dose- and time-dependent manner in HT22 cells.
Abolished the increase in mitophagy-related proteins, such as pUb and LC3 in PINK1 silenced HT22 cells.
Increased nuclear FoxO3a levels, accompanied by a concomitant decrease in cytoplasmic FoxO3a levels in HT22 cells.
Increased levels of mitochondrial marker MFN2, TIM23, and TOM20 in HT22 cells.

Western Blot Analysis^[1]

Cell Line:

Neuron-2a cells (N2a/APPswe cells)
Concentration:

5, 10, and 20 μM
Incubation Time:

24 h
Result:

Significantly reduced the levels of APP and its C-terminal fragment C99 decreased intracellular Aβ1-42 levels in a dose-dependent manner in N2a/APPswe cells.
Significantly upregulated the levels of f Parkin, PINK1, and LC3II/I in N2a/APPswe cells.

Immunofluorescence^[1]

Cell Line:

HT22 cells
Concentration:

20 μM
Incubation Time:

24 h
Result:

Significantly promoted the nuclear localization of FoxO3a.

In Vivo

Y040-7904 (500-1000 μM, 96 h) holds therapeutic potential for mitigating Alzheimer’s disease pathology in CL4176 and CL2006 worms^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Transgenic C. elegans strains CL417647 and CL2006^[1].
Dosage:

500, 1000 μM
Administration:

96 h
Result:

Resulted in a dose-dependent reduction in Aβ1-42 levels in CL4176 worms.
Decreased the paralysis rate of CL4176 worms (76.2%, 1000 μM), compared to 89.5% in untreated worm at 30 h post temperature upshift.
Reduced paralysis rate of CL2006 worms by 29.3% compared to untreated controls.

Chemical Information

CAS. Nr. 889662-19-5
Appearance Solid
Molecular Weight 370.35
Formel C₂₀H₁₈O₇
Color White to off-white
SMILES

O=C1C=C(C2=CC=CC=C2)C3=CC=C(O[C@H]4[C@@H]([C@H]([C@@H](CO4)O)O)O)C=C3O1
Synonyms

7-(β-D-Galactopyranosyloxy)-4-phenylchromen-2-one
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (270.01 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.7001 mL

13.5007 mL

27.0015 mL

5 mM

0.5400 mL

2.7001 mL

5.4003 mL

10 mM

0.2700 mL

1.3501 mL

2.7001 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 5 mg/mL (13.50 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 5 mg/mL (13.50 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 5 mg/mL (13.50 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Wang Y, et al. An AI-assisted fluorescence microscopic system for screening mitophagy inducers by simultaneous analysis of mitophagic intermediates. Nat Commun. 2025 Jun 4;16(1):5179. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.7001 mL	13.5007 mL	27.0015 mL	67.5037 mL
	5 mM	0.5400 mL	2.7001 mL	5.4003 mL	13.5007 mL
	10 mM	0.2700 mL	1.3501 mL	2.7001 mL	6.7504 mL
	15 mM	0.1800 mL	0.9000 mL	1.8001 mL	4.5002 mL
	20 mM	0.1350 mL	0.6750 mL	1.3501 mL	3.3752 mL
	25 mM	0.1080 mL	0.5400 mL	1.0801 mL	2.7001 mL
	30 mM	0.0900 mL	0.4500 mL	0.9000 mL	2.2501 mL
	40 mM	0.0675 mL	0.3375 mL	0.6750 mL	1.6876 mL
	50 mM	0.0540 mL	0.2700 mL	0.5400 mL	1.3501 mL
	60 mM	0.0450 mL	0.2250 mL	0.4500 mL	1.1251 mL
	80 mM	0.0338 mL	0.1688 mL	0.3375 mL	0.8438 mL
	100 mM	0.0270 mL	0.1350 mL	0.2700 mL	0.6750 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Y040-7904

Neuronal Signaling Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Anti-Alzheimer's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Mitochondria-Targeted Compound Library

Mitochondrial Protection Compound Library

Mitophagy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Y040-7904

Neuronal Signaling Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Anti-Alzheimer's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Mitochondria-Targeted Compound Library

Mitochondrial Protection Compound Library

Mitophagy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Y040-7904 Related Classifications

HY-174806 Related Classifications